How is the diagnosis made?
Trigeminal neuralgia is a clinical diagnosis. The key feature is a sudden and severe lancinating pain, which usually lasts from a few seconds to two minutes, within the trigeminal nerve distribution, typically the maxillary or mandibular branches (fig 1) . The pain is often evoked by trivial stimulation of appropriately named "trigger zones."
Occasionally the pain is so severe that it prevents eating or drinking. The nerves affected are usually stereotyped for a particular patient and lie within the sensory distribution of the trigeminal nerve. Box 1 lists the diagnostic criteria for the classic form of the disease.
In many cases the pain does not fit these criteria exactly because of a persistent ache between paroxysms or mild sensory loss. Such disease has been labelled as "atypical" 5 or "mixed" trigeminal neuralgia. 6 Patients with atypical disease are more likely to have symptomatic rather than idiopathic disease, and
SuMMaRy pointS
Trigeminal neuralgia is a rare but characteristic pain syndrome Most cases are still referred to as idiopathic, although many are associated with vascular compression of the trigeminal nerve A minority of cases are symptomatic of multiple sclerosis or nerve compression by tumour The condition is variable and patients may have just one episode Most patients respond well to drugs; carbamazepine is usually the first line treatment If drug treatment fails or is not tolerated, surgical treatments are available Ablative surgical treatments are associated with facial sensory loss, almost no risk of severe complications or death, and a high rate of pain recurrence; microvascular decompression has a risk of severe complications or death, albeit very low, and a lower relapse rate 3 In another 1% of patients it also affects all three divisions and rarely it can be bilateral (though paroxysms are not synchronous) they are often more refractory to treatment 6 than those with classic trigeminal neuralgia. 7 Atypical trigeminal neuralgia should not be confused with atypical facial pain (table 1) .
what causes trigeminal neuralgia?
Increasing evidence (box 2) suggests that 80-90% of cases that are technically still classified as idiopathic are caused by compression of the trigeminal nerve (fig 2) close to its exit from the brainstem by an aberrant loop of artery or vein. 5 10 Importantly, compression is of the root entry zone, where axons are coated with central nervous system myelin, rather than peripheral nerve myelin. Similarly, vascular compression of the facial and glossopharyngeal nerves is thought to be responsible for most cases of hemifacial spasm and glossopharyngeal neuralgia, respectively.
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Less than 10% of patients will have symptomatic disease associated with an identifiable cause other than a vascular compressive lesion-usually a benign tumour or cyst 10 11 -or multiple sclerosis. About 1-5% of patients with multiple sclerosis develop trigeminal neuralgia. 5 See bmj.com for an explanation of why trigeminal neuralgia is paroxysmal.
Most facial pain is not trigeminal neuralgia
Other causes of facial pain are much more common than trigeminal neuralgia. This can often lead to delay in diagnosis as patients see dentists and doctors who consider more common alternatives first.
Common causes of facial pain are usually straightforward to eliminate clinically or after dental examination ( 
Diagnosis
Important features
Dental infection or cracked tooth Well localised to tooth; local swelling and erythema; appropriate findings on dental examination Temporomandibular joint pain Often bilateral and may radiate around ear and to neck and temples; jaw opening may be limited and can produce an audible click Persistent idiopathic facial pain (previously "atypical facial pain") 4 Often bilateral and may extend out of trigeminal territory; pain often continuous, mild to moderate in severity, and aching or throbbing in character Migraine Often preceded by aura; severe unilateral headache often associated with nausea, photophobia, phonophobia, and neck stiffness
Temporal arteritis Common in elderly people; temporal pain should be constant and often associated with jaw claudication, fever, and weight loss; temporal arteries may be firm, tender, and non-pulsatile on examination
Box 2 | Evidence that vascular compression commonly causes trigeminal neuralgia 5 10 • 
what is the natural course of trigeminal neuralgia?
Because the severity of the pain demands intervention, no studies of the natural course of the disease are available. One study collected information from linked primary and secondary care records over a 40 year period. 3 They found that 29% of patients had only one episode of pain, 19% had two, 24% had three, and 28% had four to 11. Each episode lasted from one day to four years (median 49 days). After the first episode 65% of patients had a second within five years, though in 23% the gap was more than 10 years. Similar ranges of delay were seen from the second to the third event. This highlights the wide spectrum from single to frequent episodes, with each episode being of variable duration.
Most of the case series reporting surgical and other treatments for trigeminal neuralgia are from tertiary care centres and therefore represent the most severely affected patients.
what are the best medical treatments? Drug treatments for trigeminal neuralgia have been the subject of several Cochrane systematic reviews. [13] [14] [15] These reviews bring together the small number of trials available in a condition that poses difficulties for study design (box 3). Perhaps unsurprisingly the evidence is mostly weak.
Available evidence shows that carbamazepine is the drug of choice (table 3 on bmj.com). 15 17 Many patients develop adverse effects, however, though most can continue taking the drug. If the patient responds well, a controlled release preparation can be substituted and the dose can gradually be reduced.
What is less clear is what to do if a patient is intolerant or allergic to carbamazepine, or if the drug is ineffective. In the absence of clear evidence of the effectiveness of other drugs, the choice between other agents can be made on the basis of adverse effects and ease of use (table 3 on bmj.com).
If carbamazepine has adverse effects (table on bmj.com)
Oxcarbazepine is a prodrug of carbamazepine that is often better tolerated; it provides a logical, 18 if largely unproved, 17 alternative when carbamazepine has provided pain relief but has had unacceptable adverse effects. The risk of allergic crossreactivity between carbamazepine and oxcarbazepine is about 25%, so oxcarbazepine is best avoided in carbamazepine allergy.
Gabapentin is effective and widely used for neuropathic pain, though it lacks evidence in trigeminal neuralgia.
14 Use of gabapentin therefore relies on the similarities between trigeminal neuralgia and other neuropathic pain, rather than their obvious differences. Familiarity with use in other neuropathic pain has led many clinicians to choose this as second line for trigeminal neuralgia.
Lamotrigine and baclofen have been suggested as alternative second line agents on the basis of small studies in trigeminal neuralgia (see table 2 on bmj.com). In practice, lamotrigine needs to be titrated over many weeks and has limited value in severe pain. Other drugs to consider are phenytoin, clonazepam, valproate, mexiletine, and topiramate. 17 
If carbamazepine is ineffective
If pain relief is incomplete with carbamazepine options include adding a second agent or switching drugs. Similar considerations regarding choice of second line agent discussed above will apply.
Failure of medical therapy should prompt a review of the diagnosis 19 (see table 1 ). If pain control cannot be achieved or drugs cause unacceptable adverse effects, surgical options should be considered. As with most surgical procedures the literature comprises mainly case series. Such series are difficult to compare (see box 3), as they vary in the populations of patients studied; diagnostic criteria, outcome measures, and follow-up methods used; and the presentation of the data. 7 20 Despite this, broadly comparable high quality studies show relatively consistent responses to each procedure (fig 4 on bmj.com) .
Predicting outcome for individual patients with confidence is difficult. Case series suggest that patients with classic trigeminal neuralgia, evidence of vascular compression, shorter duration of disease, and no previous surgery respond better to all treatment options. 20 21 In such patients, microvascular decompression can be considered the "gold standard" surgical procedure, and it offers the best long term cure rates. Outcome also varies with the case load of operating surgeons. 22 Deciding on which procedure to use involves choosing between two different types of risk. All procedures have a high initial response rate, except for stereotactic radiosurgery, which usually takes maximum effect at one to two months (fig 4 on bmj.com) . 23 Microvascular decompression has the best chance of long term pain relief, with a very low risk of facial sensory loss and other minor complications; however, it has a small risk of death (around 0.4% 24 ). These risks vary according to other comorbidities that alter operative risk. In contrast, ablative procedures are less effective in the long term and more likely to produce facial numbness and other minor complications; indeed their effectiveness is often
•
• greatest when this is the case. 7 They have a much lower risk of death or major complication, however, and are used to a greater extent in patients with high operative risk or as a partially diagnostic procedure in atypical disease. Gamma knife stereotactic radiosurgery has recently been approved 23 by the UK's National Institute for Health and Clinical Excellence for treatment of trigeminal neuralgia, but access to this treatment is limited.
Making a decision between these options depends on the patient's perception of the two very different types of risk. Patients need to be well informed of the options, the related risks, and the likely outcomes to make such a decision. After having microvascular decompression most patients said they wish they had undergone the procedure sooner. 25 Choosing between different ablative procedures, which seem to have similar effects, may be influenced by factors such as the range of adverse effects and the way in which the procedure is undertaken (see table 4 on bmj.com).
The patient with trigeminal neuralgia who faces these difficult choices needs to be provided with the best available information and support from the doctors and surgeons involved in their care. They may find information from patient associations and other publications useful.
patient's perspective
It was 1992 when I developed pain of a "shock nature" that seemed to run around the top of my teeth on the right side. I saw the dentist who said it was nothing to do with my teeth. My doctor put me on tegretol, which made me feel like a "zombie" and I became unsteady on my feet. By now the pain was travelling in towards the brain and down towards the jaw. It was excruciating, and the only way I could "hold" the pain was to grit my teeth together very hard until the pain died away. Sleep was not interrupted, but on waking the slightest movement of the mouth would set the spasms off again, so I didn't eat or talk much. I lost a lot of weight. I went to see a neurosurgeon who advised me to have an operation to "cuff" the responsible nerve, and despite the risks I agreed as the pain was intolerable. After the operation the pain had gone. I was alive again.
Ten years later the pain returned without warning. I saw the neurosurgeon again and this time I had a "radiofrequency lesion" of my trigeminal nerve. I am at present pain free and enjoying life as much as an 86 year old man can.
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REsEARCh quEstIons
• What is the natural history of trigeminal neuralgia?
• Why do some patients with vascular compression of the trigeminal nerve get the disease and others not? • Many drugs have some effect, but which is the best drug to use? A pragmatic comparative study is needed to clarify these choices.
• Can the response to drugs and to different surgical interventions be predicted on clinical or radiological grounds? • Which ablative procedure is most effective for the fewest adverse effects?
• How do ablative procedures compare with microvascular decompression?
